Status:

UNKNOWN

Effect of Smoking Reduction on Endothelial Glucocalyx and Vascular Function

Lead Sponsor:

University of Athens

Conditions:

Smoking Cessation

Eligibility:

All Genders

18-65 years

Phase:

PHASE4

Brief Summary

The integrity of endothelial glucocalyx plays a vital role in vascular permeability and inflammation. Smoking cessation is related with improved vascular function and is a key component of secondary c...

Detailed Description

The investigators will examine smokers without cardiovascular disease treated with transdermal nicotine patches and/or varenicline at before, 4, 12, 24 and 48 weeks after treatment during validated sm...

Eligibility Criteria

Inclusion

  • Smokers

Exclusion

  • Coronary artery disease
  • Heart failure
  • Diabetes mellitus
  • Dyslipidemia

Key Trial Info

Start Date :

December 3 2014

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2020

Estimated Enrollment :

600 Patients enrolled

Trial Details

Trial ID

NCT02307045

Start Date

December 3 2014

End Date

December 1 2020

Last Update

April 3 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

''Attikon'' University General Hospital

Athens, Attica, Greece, 12462